The National Institute for Health and Care Excellence (NICE) has recommended Nucala (mepolizumab) as an add-on treatment for NHS patients with COPD. The draft final guidance recommends mepolizumab as an add-on maintenance treatment option for adult patients with uncontrolled COPD with raised blood eosinophils, if they are having a triple therapy including an inhaled corticosteroid (ICS), […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!